Multiplexed Flow Cytometry Assay for Activated GTPase Detection

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for detecting activated GTPases in viral infections and sepsis are labor-intensive, require large sample amounts, and often focus on limited subsets of GTPases, limiting the understanding of broader cell signaling changes.

Innovation Solution

A rapid, multiplexed flow cytometry-compatible bead-based effector binding assay is developed to simultaneously measure multiple activated GTPases in a single cell lysate, using effector-functionalized beads to quantify GTP-bound GTPases.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If traditional Western blot or pull-down assays are used to detect activated GTPases, then detection sensitivity can be achieved, but the method is labor-intensive and requires large sample amounts

Engineering Contradiction:
Improvedetection sensitivityVSAvoidassay speed and efficiency
Core Design Contradiction:
Measurement precisionVSProductivity

Solution Approach 1:

The patent replaces traditional mechanical Western blot procedures with flow cytometry-based detection. Specifically, it uses fluorescently labeled effectors that bind to activated GTPases in cell lysates, followed by flow cytometric analysis. This substitution eliminates labor-intensive steps such as gel electrophoresis, membrane transfer, and chemiluminescent detection, while maintaining detection sensitivity and enabling high-throughput analysis of multiple GTPases simultaneously.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

2Device complexity

If traditional methods focus on limited subsets of GTPases, then assay complexity is reduced, but the understanding of broader cell signaling changes is limited

Engineering Contradiction:
Improveassay complexityVSAvoidcomprehensive signaling information
Core Design Contradiction:
Device complexityVSLoss of information

Solution Approach 1:

The patent employs a universal flow cytometry-based platform that can detect multiple families of activated GTPases (Ras, Rho, Rab, Arf) simultaneously using different fluorescently labeled effectors. This multi-functional approach allows comprehensive analysis of cell signaling pathways in a single assay, providing broad information about cellular responses to viral infections and sepsis without requiring separate assays for each GTPase family.

Inventive Principle:
Principle #6Universality (Multi-functionality)

3Measurement precision

If large sample amounts are required for traditional assays, then detection accuracy is maintained, but clinical applicability is reduced due to limited patient sample availability

Engineering Contradiction:
Improvedetection accuracyVSAvoidclinical diagnostic applicability
Core Design Contradiction:
Measurement precisionVSAdaptability or versatility

Solution Approach 1:

The patent optimizes assay parameters to achieve accurate detection with minimal sample requirements. By using fluorescently labeled effectors and flow cytometry detection, the method achieves high sensitivity with small volumes of cell lysate or plasma samples. This parameter optimization enables clinical diagnostic applications where patient sample availability is limited, while maintaining detection accuracy through the enhanced sensitivity of flow cytometric detection.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach enables rapid, sensitive, and quantitative analysis of multiple GTPases, providing insights into the activation status of Ras, Rho, and Rab family GTPases in response to viral infections and sepsis, facilitating early diagnosis and understanding of disease mechanisms.

Implementation Method 1

Effector-functionalized beads are used to quantify in parallel multiple, GTPbound GTPases in the same cell lysate by flow cytometry

Methodology Applied
Scientific EffectProtein-protein binding: Adsorption

Implementation Method 2

multiplexed flow cytometry to detect and measure the level of active GTPase enrichment

Methodology Applied
Scientific EffectFluorescence detection: Fluorescence

Data Source

PatentUS12298305B2Activated GTPase-based assays and kits for the diagnosis of sepsis and other infections
Publication Date: 2025.05.13 UNM RAINFOREST INNOVATIONS
  • US12298305B2 patent drawing
  • US12298305B2 patent drawing
  • US12298305B2 patent drawing

AI summary

In one embodiment, the invention provides a method of diagnosing sepsis or a virus-related infection (often a viral hemorrhagic fever infection) in a subject by detecting and measuring the level of a set of sepsis and virus infection-associated-GTPase biomarkers in a sample obtained from the subject using multiplexed flow cytometry. Related kits are also provided. In a preferred embodiment, the invention provides point of care diagnostic methods for determining an early stage sepsis or the severity of a virus infection, especially in a hospital or other setting.